It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The therapeutic effects of PDA-001 in mice with chronic heart failure (CHF) were tested. Three weeks after transaortic constriction surgery to induce CHF, the mice underwent direct injection of PDA-001. Intramyocardial injection of PDA-001 significantly improved left ventricular systolic and diastolic function and decreased cardiac fibrosis, demonstrating the cardiac therapeutic potential of PDA-001.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Celgene Cellular Therapeutics, Warren, New Jersey, USA
2 Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan, Republic of China; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China
3 Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan, Republic of China